Tr2 And Tr4 Orphan Nuclear Receptors: An Overview
Shin-Jen Lin,Dong-Rong Yang,Guosheng Yang,Chang-Yi Lin,Hong-Chiang Chang,Gonghui Li,Chawnshang Chang
DOI: https://doi.org/10.1016/bs.ctdb.2017.02.002
2017-01-01
Abstract:Testicular nuclear receptors 2 and 4 (TR2, TR4), also known as NR2C1 and NR2C2, belong to the nuclear receptor superfamily and were first cloned in 1989 and 1994, respectively. Although classified as orphan receptors, several natural molecules, their metabolites, and synthetic compounds including polyunsaturated fatty acids (PUFAs), PUFA metabolites 13-hydroxyoctadecadienoic acid, 15-hydroxyeicosatetraenoic acid, and the antidiabetic drug thiazolidinediones can transactivate TR4. Importantly, many of these ligands/activators can also transactivate peroxisome proliferator-activated receptor gamma (PPAR gamma), also known as NR1C3 nuclear receptor. Both TR4 and PPAR gamma can bind to similar hormone response elements (HREs) located in the promoter of their common downstream target genes. However, these two nuclear receptors, even with shared ligands/activators and shared binding ability for similar HREs, have some distinct functions in many diseases they influence. In cancer, PPAR gamma inhibits thyroid, lung, colon, and prostate cancers but enhances bladder cancer. In contrast, TR4 inhibits liver and prostate cancer initiation but enhances pituitary corticotroph, liver, and prostate cancer progression. In type 2 diabetes, PPAR gamma increases insulin sensitivity but TR4 decreases insulin sensitivity. In cardiovascular disease, PPAR gamma inhibits atherosclerosis but TR4 enhances atherosclerosis through increasing foam cell formation. In bone physiology, PPAR gamma inhibits bone formation but TR4 increases bone formation. Together, the contrasting impact of TR4 and PPAR gamma on different diseases may raise a critical issue about drug used to target any one of these nuclear receptors.